The FDA has granted accelerated approval to Tudriqev, a new engineered viral immunotherapy for patients with treatment-resistant advanced melanoma. This therapy, used in combination with nivolumab, targets unresectable advanced cutaneous melanoma in adults who have not responded…
Recent research published in The Journal of Cosmetic Dermatology highlights a new ingredient called bakuchiol ferulate, which combines bakuchiol with ferulic acid. This study aims…
The FDA has approved Lipfendra (enlicitide), marking the first oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor for adults with high cholesterol. This approval…
The FDA has approved Lipfendra (enlicitide), the first oral therapy to inhibit PCSK9, aimed at reducing low-density lipoprotein cholesterol (LDL-C) in adults with high cholesterol…
Researchers have developed a genomic-led framework that aims to predict adverse drug reactions (ADRs) in drug development. This approach utilizes large-scale genetic datasets to i…
The FDA has granted priority review to Lipfendra, the first oral medication designed to block the PCSK9 protein, which is crucial in regulating LDL cholesterol levels. This develo…
The FDA has approved Lipfendra, the first once-daily oral PCSK9 inhibitor, which can reduce LDL cholesterol levels by 56% to 60% when used alongside statins. Developed by Merck, t…
Kem skincare has introduced a revolutionary packaging suite that demands women navigate an intricate labyrinth of beauty obligations before even touching their cream.